Stress system alterations and mood disorders in suicidal patients. A review

Biomedicine and Pharmacotherapy

Volumn 54, Issue 3, 2000, Pages 142-145

  Westrin, Å ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Delta sleep inducing peptide; Hypothalamic pituitary adrenocortical axis; Major depressive disorder; Neuropeptide Y; Noradrenaline; Stress; Suicide

Indexed keywords

AFFECTIVE NEUROSIS; DEPRESSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; REVIEW; STRESS; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT;

EID: 0034177436     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)89047-2     Document Type: Article

References (61)

1. Ågren H, Niklasson F. Suicidal potential in depression: Focus on CSF monoamine and purine metabolites. Psychopharmacol Bull 1986; 22 : 656-60.
2. Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley M, et al. Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 1990: 47 : 1038-47.
3. Arango V, Ernsberger P, Sved AF, Mann JJ. Quantitative autoradiography of alpha 1 - And alpha 2-adrenergic receptors in the cerebral cortex of controls and suicide victims. Brain Res 1993; 630 : 271-82.
4. Arango V, Underwood MD, Mann JJ. Fewer pigmented locus coeruleus neurons in suicide victims: Preliminary results. Biol Psychiatry 1996: 39: 112-20.
5. Arató M, Banki CM, Bissette G, Nemeroff CB. Elevated CSF CRF in suicide victims. Biol Psychiatry 1989; 25 : 355-9.
6. Arranz B, Blennow K, Eriksson A, Mansson JE, Marcusson J. Serotonergic, noradrenergic, and dopaminergic measures in suicide brains. Biol Psychiatry 1997; 41 : 1000-9.
7. Banki CM, Bissette G, Arato M, O'Connor L, Nemeroff CB. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 1987; 144 : 873-7.
8. Banki CM, Karmacsi L, Bissette G, Nemeroff CB. Cerebrospinal fluid neuropeptides in mood disorder and dementia. J Affect Disord 1992; 25 : 39-45.
9. Berrettini WH, Nurnberger JI Jr, Zerbe RL, Gold PW, Chrousos GP, Tomai T. CSF neuropeptides in euthymic bipolar patients and controls. Br J Psychiatry 1987; 150 : 208-12.
10. Biegon A, Israeli M. Regionally selective increases in betaadrenergic receptor density in the brains of suicide victims. Brain Res 1988; 442 : 199-203.
11. Bjartell A, Ekman R, Bergquist S, Widerlov E. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology 1989b; 14 : 347-55.
12. Bunney WE Jr, Fawcett JA. Possibility of a biochemical test for suicidal potential. Arch Gen Psychiatry 1965; 13 : 232-9.
13. Bunney WE Jr, Fawcett JA, Davis JM, Gifford S. Further evaluation of urinary 17-hydroxycorticosteroids in suicidal patients. Arch Gen Psychiatry 1969; 21 : 138-50.
14. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, HasKett RF, et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 1981; 38 : 15-22.
15. Catalán R, Gallart JM, Castellanos JM, Galard R. Plasma corticotropin-releasing factor in depressive disorders. Biol PsyChiatry 1998; 44: 15-20.
16. Charlton BG, Leake A, Ferrier IN, Linton EA, Lowry PJ. Corticotropin-releasing factor in plasma of depressed patients and controls. Lancet 1986; 1 : 161-2.
17. Coccaro EF, Astill JL. Central serotonin function in parasuicide. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14 : 663-74.
18. Deakin JFW. The role of serotonin in depression and anxiety. Eur Psychiatry 1998; 13 : 57-63.
19. De Paermentier F, Cheetham SC, Crompton MR, Katona CL, Horton RW. Brain beta-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res 1990; 525 : 71-7.
20. Dumser T, Barocka A, Schubert E. Weight of adrenal glands may be increased in persons who commit suicide. Am J Forensic Med Pathol 1998; 19 : 72-6.
21. Fawcett J, Busch KA, Jacobs D, Kravitz HM, Fogg L. Suicide: A four-pathway clinical-biochemical model. Ann NY Acad Sci 1997; 836 : 288-301.
22. France RD, Urban B, Krishnan KR, Bissett G, Banki CM, Nemeroff C, et al. CSF corticotropin-releasing factor-like immunoactivity in chronic pain patients with and without major depression. Biol Psychiatry 1988; 23 : 86-8.
23. Garvey MJ, Hollon SD, Tuason VB. Relationship between 3-methoxy-4-hydroxyphenylglycol and Suicide NeuropsychobiOlogy 1994; 29 : 112-6.
24. Grossman R, Yehuda R, Siever L. The dexamethasone suppression test and glucocorticoid receptors in borderline personality disorder. Ann NY Acad Sci 1997; 821 : 459-64.
25. Hucks D, Lowther S, Crompton MR, Katona CL, Horton RW. Corticotropin-releasing factor binding sites in cortex of depressed suicides. Psychopharmacology (Berl) 1997; 134 : 174-8.
26. Inder WJ, Donald RA, Prickett TC, Frampton CM, Sullivan PF, Mulder RT, et al. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol Psychiatry 1997; 42 : 744-7.
27. Irwin M, Brown M, Patterson T, Hauger R, Masovich A, Grant I. Neuropeptide Y and natural killer cell activity: Findings in depression and alzheimer caregiver stress. FASEB 1991; 5 : 3100-7.
28. Lester D. The dexamethasone suppression test as an indicator of suicide: A meta-analysis. Pharmacopsychiatry 1992; 25 : 265-70.
29. Lester D. The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: A meta-analysis. Pharmacopsychiatry 1995; 28 : 45-50.
30. Little KY, Ranc J, Gilmore J, Patel A, Clark TB. Lack of pineal beta-adrenergic receptor alterations in suicide victims with major depression. Psychoneuroendocrinology 1997; 22 : 53-62.
31. Lopez JF, Palkovits M, Arato M, Mansour A, Akil H, Watson SJ. Localization and quantification of pro-opiomelanocortin mrna and glucocorticoid receptor mrna in pituitaries of suicide victims. Neuroendocrinology 1992; 56 : 491-501.
32. Lopez JF, Chalmers DT, Little KY, Watson SJ. A.E. Bennett Research Award. Regulation of serotonin 1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: Implications for the neurobiology of depression. Biol Psychiatry 1998; 43 : 547-73.
33. Mann JJ, Stanley M, McBride PA, McEwen BS. Increased serotonin 2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986; 43 : 954-9.
34. Mann JJ, Malone KM. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Biol Psychiatry 1997; 41 : 162-71.
35. Mann JJ. The neurobiology of suicide. Nat Med 1998; 4 : 25-30.
36. Mancini C, Brown GM. Urinary catecholamines and cortisol in parasuicide. Psychiatry Res 1992; 43 : 31-42.
37. Meana JJ, Garcia-Sevilla JA. Increased alpha 2-adrenoceptor density in the frontal cortex of depressed suicide victims. J Neural Transm 1987; 70 : 377-81.
38. Molchan SE, Hill JL, Martinez RA, Lawlor BA, Mellow AM, Rubinow DR, et al. CSF somatostatin in Alzheimer's disease and major depression: Relationship to hypothalamic-pituitary-adrenal axis and clinical measures. Psychoneuroendocrinology 1993; 18 : 509-19.
39. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984; 226 : 1342-4.
40. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988; 45 : 577-9.
41. Pitchot W, Hansenne M, Gonzalez Moreno A, Ansseau M. The dexamethasone suppression test in violent suicide attempters with major depression. Biol Psychiatry 1995; 37 : 273-4.
42. Pitts AF, Samuelson SD, Meller WH, Bissette G, Nemeroff CB, Kathol RG. Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Biol Psychiatry 1995; 38 : 330-5.
43. Regnéll G, Widerlöv E, Ekman R. Delta sleep-inducing peptide in CSF of patients with affective illness is elevated by lithium treatment. Biol Psychiatry 1988; 24 : 112.
44. Roy A, Pickar D, Paul S, Doran A, Chrousos GP, Gold PW. CSF corticotropin-releasing hormone in depressed patients and normal control subjects. Am J Psychiatry 1987; 144 : 641-5.
45. Roy A, Pickar D, De Jong J, Karoum F, Linnoila M. Suicidal behavior in depression: Relationship to noradrenergic function. Biol Psychiatry 1989; 25 : 341-50.
46. Roy A. Hypothalamic-pituitary-adrenal axis function and suicidal behavior in depression. Biol Psychiatry 1992; 32 : 812-6.
47. Roy A. Neuropeptides in relation to suicidal behavior in depression. Neuropsychobiology 1993; 28 : 184-6.
48. Ruggiero DA, Underwood MD, Rice PM, Mann JJ, Arango V. Corticotropic-releasing hormone and serotonin interact in the human brainstem: Behavioral implications. Neuroscience 1999; 4: 1343-54.
49. Stein E, McCrank E, Schaefer B, Goyer R. Adrenal gland weight and suicide. Can J Psychiatry 1993; 38 : 563-6.
50. Stockmeier CA, Meltzer HY. Beta-adrenergic receptor binding in frontal cortex of suicide victims. Biol Psychiatry 1991; 29 : 183-91.
51. Stratakis CA, Chrousos GP. Neuroendocrinology and pathophysiology of the stress system. Ann NY Acad Sci 1995; 771 : 1-18.
52. Szigethy E, Conwell Y, Forbes NT, Cox C, Caine ED. Adrenal weight and morphology in victims of completed suicide. Biol Psychiatry 1994; 36 : 374-80.
53. Träskman-Bendz L, Ekman R, Regnell G, Ohman R. Hpa-related CSF neuropeptides in suicide attempters. Eur Neuropsychopharmacol 1992; 2 : 99-106.
54. Walléus H, Widerlöv E, Ekman R. Decreased concentrations of the delta-sleep inducing peptide in plasma and cerebrospinal fluid from depressed patients. Nord Psychiatr Tidsskr 1985; 39 Suppl 11 : 63-7.
55. Van Bockstaele EJ, Colago EEO, Valentino RJ. Corticotropin-releasing factor-containing axon terminals synapse onto catecholamine dendrites and may presynaptically modulate other afferents in the rostral pole of the nucleus locus coeruleus in the rat brain. J Comp Neurol 1996; 364 : 523-34.
56. Van Praag HM. Faulty cortisol/serotonin interplay. Psychopathological and Biological Characterisation of a New, Hypothetical Depression Subtype (Seca-depression). Psychiatry Res 1996; 65 : 143-57.
57. Westrin A, Ekman R, Traskman-Bendz L. High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder. Biol Psychiatry 1998; 43 : 734-9.
58. Westrin A, Ekman R, Traskman-Bendz L. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. Eur Neuropsychopharmacol 1999; 9 : 205-11.
59. Widerlöv E, Wahlestedt C, Hakansson R, Ekman R. Altered brain neuropeptide function in psychiatric illnesses with special emphasis on NPY and CRF in major depression. Clin Neuropharmacol 1986; Suppl 4 : 572-4.
60. Widerlöv E, Bissette G, Nemeroff CB. Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients. J Affect Disord 1988; 14 : 99-107.
61. Zukowska-Grojec Z, Wahlestedt C. Origin and actions of neuropeptide Y in the cardiovascular system. In: Colmers WF, Wahlestedt C, eds. The Biology of Neuropeptide Y. Totowa, New Jersey: Humana Press; 1993. p. 315-88.